Face vs Body
Body use is not facial use over a larger surface area. The face, neck, décolletage, hands, arms, abdomen, buttocks, thighs, and knees differ in anatomy, tissue thickness, movement, objective, preparation, evidence, and regulatory status.
Separate area from objective
Section titled “Separate area from objective”| Area family | Commonly discussed objective | Key distinction |
|---|---|---|
| Face | Wrinkle or fold correction, contour support, volume restoration, defined skin attribute | Dense vascular anatomy and product-specific facial indications |
| Neck and décolletage | Wrinkle, laxity, elasticity, or surface quality | Thin mobile tissue and highly region-specific evidence |
| Hands and arms | Dorsal-hand volume or upper-arm skin attributes | Hand volume and arm laxity are different objectives |
| Abdomen, buttocks, thighs, knees | Skin laxity, contour, depressions, or cellulite appearance | Large surface area does not create one dose or technique |
Do not collapse a wrinkle indication, skin-depression correction, cellulite appearance, and large-scale contour augmentation into “body treatment.”
Current regulatory examples
Section titled “Current regulatory examples”Regional scope changes the interpretation:
- European Union: Galderma announced Sculptra MDR certification on December 5, 2025 with expansion to the gluteal area, posterior thighs, décolletage, and upper arms (Galderma 🔗).
- United States: Radiesse received a specific March 31, 2026 indication for 1:2 diluted product in décolleté wrinkles in patients 22 years and older (FDA P050052/S162 🔗).
- United States generally: the FDA states that injectable fillers are not approved for body contouring or enhancement and lists several unapproved uses (FDA dermal-filler information 🔗).
The regulated décolleté-wrinkle example should not be rewritten as broad US body-contouring approval.
Evidence examples are product- and area-specific
Section titled “Evidence examples are product- and area-specific”A prospective, open-label Lanluma post-market study included neck, décolletage, upper arms, hands, thighs, and related areas. It had no untreated control and reported treatment-related lumps and nodules, so it supports bounded observational experience rather than a universal body protocol (Lanluma study 🔗).
A randomized split-body PLLA study evaluated upper-knee and lower-thigh skin laxity (split-body PLLA laxity study 🔗). That anatomy and objective do not establish buttock contour, abdominal laxity, or facial wrinkle outcomes.
Expert recommendations for off-face PLLA acknowledge limited evidence and call for further investigation of efficacy and durability (off-face PLLA recommendations 🔗).
Presentation becomes more visible in body planning
Section titled “Presentation becomes more visible in body planning”Confirm:
- exact vial or syringe presentation
- final concentration and permitted preparation
- whether the studied presentation matches the current product
- surface area and distribution objective
- tissue thickness and movement
- product traceability across multiple units
- planned photography, reassessment, and complication access
Lanluma V and X have different PLLA amounts. Sculptra preparation cannot be substituted for Lanluma, and a face protocol cannot be enlarged into a body protocol.
Safety interpretation also changes by area
Section titled “Safety interpretation also changes by area”Different regions change vascular anatomy, depth uncertainty, product visibility, palpability, mechanical stress, infection assessment, and the clinical impact of a nodule or contour irregularity.
Use patient selection, documentation and follow-up, and the nodule framework with the exact area recorded.
Decision output
Section titled “Decision output”Before proceeding, document the exact area, objective, local label, product presentation, evidence match, practitioner training, emergency plan, and follow-up capacity.